Company intelligence / Profile preview

Sichuan Puruite Pharmaceutical Technology

Chengdu, Sichuan, China

Ownership: Private
Development stage: Other

Overview

Sichuan Puruite Pharmaceutical Technology is a China-based biotechnology company focused on the research and development of innovative small molecule drugs, particularly in the field of oncology. The company specializes in the discovery of targeted therapies, with a notable focus on fibroblast growth factor receptor (FGFR) inhibitors for the treatment of solid tumors and hepatocellular carcinoma. Its lead candidate, PRT-01, is a highly selective FGFR4 inhibitor currently undergoing clinical evaluation. Puruite Pharmaceutical operates out of the Chengdu Hi-Tech Zone, leveraging local R&D infrastructure to advance its pipeline of precision medicines.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Sichuan Puruite Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sichuan Puruite Pharmaceutical Technology.

Explore the full profile